Non-clinical pharmacokinetic/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab

Drug Research

Volumn 64, Issue 11, 2014, Pages 569-575

  Bittner, B ^a   Richter, W F ^a   Hourcade Potelleret, F ^a   Herting, F ^b   Schmidt, J ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

clinical trials; dose finding; follicular lymphoma; intravenous; pharmacology; preclinical studies

Indexed keywords

RITUXIMAB;

AREA UNDER THE CURVE; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; FOLLICULAR LYMPHOMA; HUMAN; MACACA FASCICULARIS; MAINTENANCE CHEMOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84909630702     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0033-1363993     Document Type: Review

References (23)

1. Maloney D. G., Grillo-López A. J., White C. A. et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood: 1997; 90 2188 2195
2. Plosker G. L., Figgitt D. P. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs: 2003; 63 803 843
3. Coiffier B., Lepage E., Brière J. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med: 2002; 346 235 242
4. Shivakumar S. P., Anderson D. R., Couban S. Catheter-associated thrombosis in patients with malignancy. J Clin Oncol: 2009; 27 4858 4864
5. Barber N. D., Hoffmeyer U. K. Comparison of the cost-effectiveness of administering heparin subcutaneously or intravenously for the treatment of deep vein thrombosis. Ann R Coll Surg Engl: 1993; 75 430 433
6. Pivot X., Gligorov J., Muller V. et al. Patient preference for subcutaneous versus intravenous adjuvant trastuzumab: results of the PREFHER study. The Breast: 2013; 22 01 S87 (Abstract 207)
7. Bittner B., Richter W. F., Hourcade-Potelleret F. et al. Development of a subcutaneous formulation for trastuzumab - nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Arzneimittelforschung: 2012; 62 401 409
8. Wynne C., Harvey V., Schwabe C. et al. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol: 2012; [epub ahead of print] 10.1177/0091270012436560
9. Ismael G., Hegg R., Muehlbauer S. et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicenter, randomized trial. Lancet Oncol: 2012; 13 869 878
10. MabThera™ (rituximab) summary of product characteristics: 2009; Available from http://www.mabthera.com/portal/mabthera/safety-information
11. Dani B., Platz R., Tzannis S. T. High concentration formulation feasibility of human immunoglobulin G for subcutaneous administration. J Pharm Sci: 2007; 96 1504 1517
12. Shire S. J., Shahrokh Z., Liu J. Challenges in the development of high protein concentration formulations. J Pharm Sci: 2004; 93 1390 1402
13. Frost G. I. Recombinant human hyaluronidase (rHuPH20): An enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv: 2007; 4 427 440
14. By Adler M., Mahler H-C, Stauch O. B. Highly concentrated pharmaceutical formulations. Patent application submitted in the European Union (Patent application number: 20110076273). Available at: http://www.faqs.org/patents/app/20110076273
15. Zheng Y., Tesar D. B., Benincosa L. et al. Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. MAbs: 2012; 4 243 255
16. th Annual Meeting and Exposition of the Controlled Release Society 2007, held 7-11 July 2007, Long Beach, California
17. Mao C. P., Brovarney M. R., Dabbagh K. et al. Subcutaneous versus intravenous administration of rituximab: Pharmacokinetics, CD20 target coverage and B-cell depletion in Cynomolgus monkeys. PlosOne [accepted]
18. Tucker C. A., Bebb G., Klasa R. J. et al. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leuk Res: 2006; 30 449 457
19. Ng C. M., Lum B. L., Gimenez V. et al. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res: 2006; 23 1275 1284
20. Wang D. D., Zhang S., Zhao H. et al. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol: 2009; 49 1012 1024
21. Salar A., Bouabdallah R., McIntyre C. et al. A two-stage phase Ib study to investigate the pharmacokinetics, safety and tolerability of subcutaneous rituximab in follicular lymphoma as part of maintenance treatment. Blood: 2010; 116 (Abstract 2858)
22. Salar A., Avivi I., Larouche J. F. et al. Final results of the BP22333 study demonstrate non-inferior pharmacokinetics and safety of subcutaneous administration of rituximab compared with intravenous administration as maintenance therapy in patients with follicular lymphoma. Blood: 2012; 120 (Abstract 1641)
23. Davies A., Merli F., Mihaljevic B. et al. Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follicular lymphoma (FL) in the first-line setting: stage 1 results of the phase III SABRINA study (BO22334). Blood: 2012; 120 (Abstract 1629)